Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Preferred Stock Liabilities (2022 - 2024)

Historic Preferred Stock Liabilities for Insight Molecular Diagnostics (IMDX) over the last 3 years, with Q1 2024 value amounting to $5.3 million.

  • Insight Molecular Diagnostics' Preferred Stock Liabilities changed N/A to $5.3 million in Q1 2024 from the same period last year, while for Mar 2024 it was $5.3 million, marking a year-over-year change of. This contributed to the annual value of $5.1 million for FY2023, which is 331.95% down from last year.
  • According to the latest figures from Q1 2024, Insight Molecular Diagnostics' Preferred Stock Liabilities is $5.3 million.
  • Over the past 5 years, Insight Molecular Diagnostics' Preferred Stock Liabilities peaked at $5.3 million during Q1 2024, and registered a low of $4.7 million during Q2 2023.
  • In the last 3 years, Insight Molecular Diagnostics' Preferred Stock Liabilities had a median value of $5.1 million in 2022 and averaged $5.1 million.
  • Data for Insight Molecular Diagnostics' Preferred Stock Liabilities shows a peak YoY increase of 301.42% (in 2023) and a maximum YoY decrease of 331.95% (in 2023) over the last 5 years.
  • Quarter analysis of 3 years shows Insight Molecular Diagnostics' Preferred Stock Liabilities stood at $5.3 million in 2022, then dropped by 3.32% to $5.1 million in 2023, then grew by 4.02% to $5.3 million in 2024.
  • Its Preferred Stock Liabilities stands at $5.3 million for Q1 2024, versus $5.1 million for Q4 2023 and $4.9 million for Q3 2023.